Fuji Corporation
Financial Results Explanation Materials for the Fiscal Period Ending March 2026 – Interim Report
In the interim results for the fiscal period ending March 2026, revenue reached 180.7 billion yen, net income was 15.7 billion yen, both increasing compared to the same period last year. Segments such as pharmaceuticals and imaging business performed well. Full-year forecasts have also been revised upward, maintaining stable performance.
Key Figures
- Revenue: 180.7 billion yen (YoY +16.8%)
- Net Income: 15.7 billion yen (YoY +44.3%)
- Operating Income: 29.2 billion yen (YoY +112.5%)
AI要約
Performance Overview
The interim financial results for the fiscal period ending March 2026 achieved significant growth with revenue of 180.7 billion yen (YoY +16.8%) and net income of 15.7 billion yen (YoY +44.3%). The pharmaceuticals and imaging segments performed well, with particularly strong contributions from pharmaceutical sales expansion. Post-pandemic demand recovery and new product launches led to record-high profits. Full-year forecasts have been revised upward, supporting sustained solid performance.
Future Outlook and Investor Impact
Full-year earnings are projected at revenue of 211.0 billion yen and net income of 33.0 billion yen, continuing to be robust. Expansion into new businesses and overseas markets are strengthening growth foundations. For investors, this indicates a stable profit base and growth potential, increasing long-term investment attractiveness. Shareholder return policies will include increased dividends, reflecting a focus on enhancing shareholder value.
Revenue Trend
Net Income Trend
Segment Revenue Breakdown
Full-Year Forecast vs. Actual
Fujifilm Corporation
Company overview · Stock price · Financial data · All IR
